DIFP-FA + US triggers immune activation, increasing CD4+ and CD8+ cell infiltration within the tumor tissue, while the anti-PD-1 antibody alters the inhibitory TME, enabling the immune system to more effectively recognize and eliminate tumor cells, thus achieving effective clearance of cisplatin-gemcitabine and tislelizumab-resistant BC. Here, CD4 is linked to breast cancer.